Showing results (111-120 of 176) with videos related to
Sort By:
Pageof 18
Cancer Chemotherapy and Pharmacology|January 30, 2014
The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjectsMarta Hamilton, Julie L Wolf, Daniel W Drolet, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|December 31, 2005
Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteersJie Ling, Kim A Johnson, Zhuang Miao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1983
Weekly doxorubicin in endocrine-refractory carcinoma of the prostateF M Torti, D Aston, B L Lum, et al.World Journal of Transplantation|June 19, 2025
C3 glomerulopathy post kidney transplantation: A single center experienceJonathan Zuckerman, Phuong-Thu Pham, Meena Parakkal, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2003
Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignanciesRanjana Advani, George A Fisher, Bert L Lum, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1994
Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistanceN L Bartlett, B L Lum, G A Fisher, et al.European Journal of Clinical Pharmacology|November 15, 2007
The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibitionAshok Rakhit, Michael P Pantze, Scott Fettner, et al.Breast Cancer Research and Treatment|December 16, 2003
Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancerAnne-Renee Hartman, Amy Grekowicz, Bert L Lum, et al.Experimental Hematology|July 1, 1993
Expansion of neutrophil precursors and progenitors in suspension cultures of CD34+ cells enriched from human bone marrowS L Smith, J G Bender, P B Maples, et al.Anti-Cancer Drugs|March 19, 2014
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancerHilary Calvert, Chris Twelves, Malcolm Ranson, et al.Pageof 18